Buscar
Longeveron Inc
LGVNAñadir a la lista de seguimiento
0.702USD
+0.026+3.88%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
22.17MCap. mercado
PérdidaP/E TTM
Más Datos de Longeveron Inc Compañía
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Información de Longeveron Inc
Símbolo de cotizaciónLGVN
Nombre de la empresaLongeveron Inc
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección1951 NW 7th Ave
CiudadMIAMI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33136
Teléfono13053027158
Sitio Webhttps://www.longeveron.com/
Símbolo de cotizaciónLGVN
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Ejecutivos de Longeveron Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
332.64K
-6.77%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
320.37K
-7.02%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
286.30K
-5.52%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
256.46K
+2.07%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
--
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
13.58K
--
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Mr. Paul Lehr, J.D.
Mr. Paul Lehr, J.D.
General Counsel and Secretary
General Counsel and Secretary
--
--
Mr. Than Powell
Mr. Than Powell
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
332.64K
-6.77%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
320.37K
-7.02%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
286.30K
-5.52%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
256.46K
+2.07%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
--
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Longeveron Inc?
Los cinco principales accionistas de Longeveron Inc son: Ms. Lisa Locklear
¿Cuántas instituciones poseen acciones de Longeveron Inc (LGVN)?
A fecha de 2026Q1, 62 instituciones poseen acciones de Longeveron Inc, con un valor de mercado combinado de aproximadamente 2.25M, lo que representa el 8.08% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1131825.00.
¿Cuál es la mayor fuente de ganancias de Longeveron Inc?
El 2026Q1, el segmento empresarial Clinical trial revenue generó la ganancia más alta para Longeveron Inc, ascendiendo a 954.00K y representando el 79.57% de la ganancia total.